Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer.
10.5230/jgc.2013.13.3.129
- Author:
Jae Yong CHO
1
Author Information
1. Department of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. chojy@yuhs.ac
- Publication Type:Review
- Keywords:
Stomach neoplasms;
Therapeutics;
Biological markers;
Gene expression;
Sequence analysis
- MeSH:
Axis, Cervical Vertebra;
Biomarkers;
Gene Expression;
Humans;
Pathology, Molecular;
Phosphatidylinositols;
Prognosis;
Receptor, Epidermal Growth Factor;
Sequence Analysis;
Sirolimus;
Stomach Neoplasms
- From:Journal of Gastric Cancer
2013;13(3):129-135
- CountryRepublic of Korea
- Language:English
-
Abstract:
Gastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conventional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clinical benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Numerous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epidermal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, is mandatory to recognize personalized target therapy.
